 The study suggests that mycophenolate moftil, MMF, may be an effective treatment option for severe cases of atopic dermatitis, with a significant reduction in pre-to-post-scorad scores and a high rate of partial or full remission. However, the evidence is low quality and ongoing monitoring for potential complications such as herpes infections is necessary, particularly with prolonged duration of treatment. This article was authored by Kevin Fan and Saxon D Smith.